Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, said it arranged securities purchase agreements with unnamed institutional investors for a registered direct offering of 1.17 million common shares and a concurrent private placement of warrants to purchase 760,500 additional common shares at a combined price of $3.10 for one common share and each warrant, generating gross proceeds of $3.6 million.